CN109069450A - 神经障碍的新的组合疗法 - Google Patents

神经障碍的新的组合疗法 Download PDF

Info

Publication number
CN109069450A
CN109069450A CN201780010107.6A CN201780010107A CN109069450A CN 109069450 A CN109069450 A CN 109069450A CN 201780010107 A CN201780010107 A CN 201780010107A CN 109069450 A CN109069450 A CN 109069450A
Authority
CN
China
Prior art keywords
piperazine
acamprosate
quinolone
base
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780010107.6A
Other languages
English (en)
Chinese (zh)
Inventor
D.科恩
S.纳比罗奇金
R.哈吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fa Nai Ces Co Ltd
Original Assignee
Fa Nai Ces Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fa Nai Ces Co Ltd filed Critical Fa Nai Ces Co Ltd
Publication of CN109069450A publication Critical patent/CN109069450A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780010107.6A 2016-02-05 2017-02-03 神经障碍的新的组合疗法 Pending CN109069450A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPEP16305128.7 2016-02-05
EP16305128 2016-02-05
EPEP17152720.3 2017-01-23
EP17152720 2017-01-23
PCT/EP2017/052470 WO2017134280A1 (en) 2016-02-05 2017-02-03 Novel combinatorial therapies of neurological disorders

Publications (1)

Publication Number Publication Date
CN109069450A true CN109069450A (zh) 2018-12-21

Family

ID=58044028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780010107.6A Pending CN109069450A (zh) 2016-02-05 2017-02-03 神经障碍的新的组合疗法

Country Status (6)

Country Link
US (1) US10799499B2 (https=)
JP (1) JP7027318B2 (https=)
CN (1) CN109069450A (https=)
AU (1) AU2017216288B2 (https=)
CA (1) CA3012900A1 (https=)
WO (1) WO2017134280A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007607A (zh) * 2019-02-05 2022-02-01 加州大学评议会 用于治疗神经变性疾病的材料和方法
CN114181201A (zh) * 2020-09-15 2022-03-15 香港科技大学 作为针对各种神经退行性疾病的潜在治疗剂的新化合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746062A1 (en) * 2018-01-29 2020-12-09 Pharnext Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
WO2025151884A1 (en) * 2024-01-12 2025-07-17 Parsons C Lowell Use of glycosaminoglycan sulfated polysaccharides such as sodium pentosan polysulfate in combination with permeation agents to treat alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009074607A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2796132A1 (en) * 2011-03-01 2014-10-29 Pharnext Baclofen and acamprosate based therapy of neurological disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2309154C9 (ru) * 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
TWI369982B (en) * 2007-01-11 2012-08-11 Xenoport Inc Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2008087123A2 (en) * 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
PL2282778T3 (pl) * 2008-04-29 2017-08-31 Pharnext Nowe podejścia terapeutyczne do leczenia choroby alzheimera i powiązanych zaburzeń poprzez modulację angiogenezy
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009074607A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2796132A1 (en) * 2011-03-01 2014-10-29 Pharnext Baclofen and acamprosate based therapy of neurological disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAG NYHOLM等: "Levodopa Infusion Therapy in Parkinson Disease", 《CLINICAL NEUROPHARMACOL》 *
KRISTA L. LANCTOT等: "Therapy for Alzheimer’s disease: how effective are current treatments？", 《THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007607A (zh) * 2019-02-05 2022-02-01 加州大学评议会 用于治疗神经变性疾病的材料和方法
CN114181201A (zh) * 2020-09-15 2022-03-15 香港科技大学 作为针对各种神经退行性疾病的潜在治疗剂的新化合物
CN114181201B (zh) * 2020-09-15 2023-12-01 香港科技大学 作为针对各种神经退行性疾病的潜在治疗剂的新化合物

Also Published As

Publication number Publication date
AU2017216288A1 (en) 2018-08-09
US20190111054A1 (en) 2019-04-18
JP7027318B2 (ja) 2022-03-01
CA3012900A1 (en) 2017-08-10
AU2017216288B2 (en) 2022-06-02
WO2017134280A1 (en) 2017-08-10
US10799499B2 (en) 2020-10-13
JP2019504101A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
CN105744932B (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
KR101937782B1 (ko) 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
KR101918669B1 (ko) 신경 장애 치료용 신규 조성물
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
CN106456583A (zh) 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合
CN107810002A (zh) 左乙拉西坦的延时释放药物组合物
US9931326B2 (en) Composition comprising torasemide and baclofen for treating neurological disorders
CN109069450A (zh) 神经障碍的新的组合疗法
JP2019504101A5 (https=)
JP7065880B2 (ja) アルツハイマー病のイダロピルジン系組合せ療法
EP3411025A1 (en) Novel combinatorial therapies of neurological disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221